Nucleus Network Acquires Hammersmith Medicines Research
Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network's global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804665702/en/
The acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents.
'We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy,' said Teena Pisarev, Chief Executive Officer of Nucleus Network . 'This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.'
A New Standard for Early-Phase Clinical Trials
With the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk.
The expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites.
Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network's position as the most experienced global provider dedicated to early-phase clinical research.
At the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies.
' This acquisition expands what's possible for our sponsors,' Pisarev added. 'It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.'
Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships.
About Nucleus Network
Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation.
For more information, visit: www.nucleusnetwork.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20250804665702/en/
CONTACT: Media ContactDani Stoltzfus
Mighty Spark Communications
Email:[email protected] Campbell
EVP Marketing & Communications
Nucleus Network
Email:[email protected]
KEYWORD: UNITED STATES UNITED KINGDOM AUSTRALIA/OCEANIA AUSTRALIA NEW ZEALAND IRELAND NORTH AMERICA CANADA EUROPE MINNESOTA
INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH GENERAL HEALTH PHARMACEUTICAL HEALTH TECHNOLOGY OTHER SCIENCE MEDICAL DEVICES RESEARCH SCIENCE CLINICAL TRIALS
SOURCE: Nucleus Network
Copyright Business Wire 2025.
PUB: 08/04/2025 04:00 AM/DISC: 08/04/2025 04:00 AM
http://www.businesswire.com/news/home/20250804665702/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Joby Aviation (JOBY) Jumps to New High on $125-Million Acquisition of Air Mobility Platform
We recently published . Joby Aviation, Inc. (NYSE:JOBY) is one of the companies that stood stronger last week. Joby Aviation saw its share prices surge to a new all-time high on Monday following announcements that it was set to acquire a leading urban air mobility platform for $125 million. At intraday trading, the company rose by as much as 22 percent to $20.95, before paring gains to end the day just up by 18.82 percent at $20.39 apiece. In a statement, Joby Aviation, Inc. (NYSE:JOBY) said it entered into a definitive agreement with Blade Air Mobility, Inc. for the acquisition of its urban air mobility passenger business. The acquisition will exclude Blade's Medical division, but it will remain an important partner for medical transportation purposes. According to Joby Aviation, Inc. (NYSE:JOBY), the acquisition would unlock immediate market access and infrastructure across New York City and Southern Europe, and complement its planned launch in Dubai next year. Last year alone, Blade flew more than 50,000 passengers from a network of 12 terminals across the US. Copyright: khunaspix / 123RF Stock Photo 'With access to the infrastructure they have secured and the loyal customer base they have developed, we will be in the best possible position to launch our quiet, electric aircraft as soon as certification is secured,' Joby Aviation, Inc. (NYSE:JOBY) founder and CEO JoeBen Bevirt said. While we acknowledge the potential of JOBY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28 minutes ago
- Yahoo
Onto Innovation (ONTO) Announces Definitive Agreement To Acquire Materials Analysis Business of Semilab International
Onto Innovation Inc. (NYSE:ONTO) is one of the Most Undervalued Semiconductor Stocks to Buy According to Analysts. On June 30, the company announced that it had entered into a definitive agreement for the acquisition of the materials analysis business of Semilab International for $475 million in cash and 706,215 shares of Onto Innovation Inc. (NYSE:ONTO) common stock. The acquisition adds 4 complementary product lines offering inline wafer contamination monitoring as well as materials interface characterization. A technician observing a macro defect inspection process, the precision of the company's systems. With the use of exotic materials in semiconductor manufacturing expanding rapidly, the demand for advanced materials analysis continues to grow significantly. Furthermore, the acquisition aligns with Onto Innovation Inc. (NYSE:ONTO)'s strategy to excel in high-growth, high-margin segments of the semiconductor value chain, mainly areas where device complexity has been accelerating, like the production of chips needed for AI applications. The transaction is anticipated to be immediately accretive to both gross and operating margins and to improve non-GAAP EPS by over 10% in the first year following close, adding more than $130 million to Onto Innovation Inc. (NYSE:ONTO)'s annual revenue. Invesco Distributors, Inc., an investment management firm, released Q4 2024 investor letter. Here is what the fund said: 'Onto Innovation Inc. (NYSE:ONTO): The company is a semiconductor capital equipment manufacturer that provides process control solutions for microelectronics manufacturing, including defect inspection, metrology systems and software to enhance yield and reduce costs. The company has benefited from the artificial intelligence (AI) boom, but weakness during the quarter provided an attractive entry point for the fund.' While we acknowledge the potential of ONTO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Steelcase (SCS) Soars to New High on $2.2-Billion Merger With HNI Corp.
We recently published . Steelcase Inc. (NYSE:SCS) is one of the companies that stood stronger last week. Steelcase skyrocketed by 62.87 percent to touch a new all-time high on Monday as investors gobbled up shares following news that it was set to be acquired by HNI Corporation for $2.2 billion. During the session, its share prices rallied by as high as 68 percent at $17.13 before paring gains to end the day at $16.58 apiece. In a statement on the same day, HNI Corporation announced that it entered into a definitive agreement with Steelcase Inc. (NYSE:SCS), under a combination of cash and stock transaction. Under the terms, shareholders of Steelcase Inc. (NYSE:SCS) will receive $7.20 in cash and 0.2192 shares of HNI common stock for each SCS common share held. The implied per share purchase price of $18.30 was based on HNI's closing share price of $50.62 on Friday, August 1, 2025, reflecting a valuation multiple at transaction close for Steelcase of approximately 5.8x. Copyright: archidea / 123RF Stock Photo Upon completion, the two parties expect the combined company to have a pro forma annual revenue of approximately $5.8 billion, pro forma Adjusted EBITDA of approximately $745 million, and 2.1x net leverage. While we acknowledge the potential of SCS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
